Drug
Venetoclax
Venetoclax: highest development phase Phase 3, developed by AbbVie, Bristol-Myers Squibb, TG Therapeutics. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- AbbVie, Bristol-Myers Squibb, TG Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Venetoclax NCT02980731 | Phase 3 | Chronic Lymphocytic Leukemia (CLL) |
| Venetoclax NCT02966756 | Phase 2 | Chronic Lymphocytic Leukemia (CLL) |
| Venetoclax NCT03379051 | Phase 1/2 | Chronic Lymphocytic Leukemia |
| Venetoclax NCT02951117 | Phase 1 | Multiple Myeloma |
| Venetoclax NCT05287568 | Phase 1 | AML |
Latest
No recent events.
Follow Venetoclax on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.